BRIEF-Shanghai Henlius Biotech SAys FDA Approves IND Application For Henlius' Biosimilar Hlx17

Reuters
Sep 08
BRIEF-<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> SAys FDA Approves IND Application For Henlius' Biosimilar Hlx17

Sept 8 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:

  • FDA APPROVES IND APPLICATION FOR HENLIUS' BIOSIMILAR HLX17

  • IND APPLICATION FOR PHASE 1 TRIAL OF BIOSIMILAR OF PEMBROLIZUMAB HLX17 APPROVED BY FDA

Further company coverage: 2696.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10